We are live on !
Find out more
Bender Robert & Associates Portfolio holdings
AUM
$525M
Turnover
26.53%
1-Year Est. Return
38.43%
This Fund
S&P 500
This Quarter Est. Return
+7.49%
1 Year Est. Return
+38.43%
3 Year Est. Return
+145.82%
5 Year Est. Return
+189.35%
10 Year Est. Return
+1,046.87%
AUM
$180M
AUM Growth
+$6.46M
(+3.7%)
Cap. Flow
-$2.04M
Cap. Flow % of AUM
Cap. Flow %
-1.13%
Top 10 Holdings %
Top 10 Hldgs %
57.53%
Holding
51
New
2
Increased
3
Reduced
42
Closed
1
Avg Time Held
3.9
years
Top 10 Avg Time Held
2.8
years
Top 20 Avg Time Held
3.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caterpillar
CAT
|
+$196K |
| 2 |
Deere & Co
DE
|
+$190K |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$52.4K |
| 4 |
VMW
VMware, Inc
VMW
|
+$10.1K |
| 5 |
Adobe
ADBE
|
+$2.06K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAVM
Cavium, Inc.
CAVM
|
+$381K |
| 2 |
KITE
Kite Pharma, Inc.
KITE
|
+$366K |
| 3 |
Intuitive Surgical
ISRG
|
+$229K |
| 4 |
Mercado Libre
MELI
|
+$217K |
| 5 |
CELG
Celgene Corp
CELG
|
+$165K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.65% |
| 2 | Technology | 25.32% |
| 3 | Consumer Discretionary | 24.58% |
| 4 | Communication Services | 13.24% |
| 5 | Industrials | 3.18% |
Similar funds
A
H2CM
Bender Robert & Associates's Q4 2017 Portfolio in Review
As of Q4 2017, Bender Robert & Associates held 51 positions worth $180M, up 3.7% from $174M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Bender Robert & Associates's Q4 2017 filing shows 2 new, 3 increased, 42 reduced and 1 closed positions. Its largest new stake was Caterpillar: 1,414 shares worth $223K. The largest sale was Cavium, Inc., an estimated $381K.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 35% a quarter earlier, followed by Technology and Consumer Discretionary.
- Bender Robert & Associates's largest Q4 2017 buy was Caterpillar: 1,414 shares worth $223K.
- Bender Robert & Associates added most to Alexion Pharmaceuticals in Q4 2017, an estimated $52.4K increase.
- Bender Robert & Associates's biggest Q4 2017 reduction was Cavium, Inc., cutting an estimated $381K.
- Bender Robert & Associates fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $366K.
- Bender Robert & Associates's ten largest holdings make up 58% of its $180M portfolio in Q4 2017.
- Bender Robert & Associates opened 2 new positions and closed 1 in Q4 2017.
- Bender Robert & Associates's portfolio value rose 3.7% quarter-over-quarter to $180M.
Based on Bender Robert & Associates's 13F filing for Q4 2017, filed 19 Jan 2018.